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Abstract Interleukin-7 is a potent regulator of lympho-
cyte proliferation, but it inducing growth of solid tumors is
few known. We study the relationship between Interleukin-
7 and the regulator of the cell cycle, cyclin D1 and the
mechanism of Interleukin-7 regulating cell growth in
human lung cancer. We detected expression of cyclin D1
and its impact on the prognosis of lung cancer patients.
Using Western blot, reverse transcriptase-PCR, Co-
Immunoprecipitation, and Chromatin Immunoprecipita-
tion, we investigated how Interleukin-7 regulated cyclin D1
in vitro and in nude mice. We found that, in lung cancer
cell lines and in nude mice, Interleukin-7/Interleukin-7
receptor increased the expression of cyclin D1 and phos-
phorylation of c-Fos/c-Jun, induce c-Fos and c-Jun
heterodimer formation, and enhanced c-Fos/c-Jun DNA-
binding activity to regulate cyclin D1. In addition, lymph
node metastasis, tumor stage, and cyclin D1 were the
strongest predictors of survival in 100 human non-small
cell lung cancer specimens analyzed. Taken together, our
results provided evidence that Interleukin-7/Interleukin-7
receptor induced cyclin D1 up-regulation via c-Fos/c-Jun
pathway to promote proliferation of cells in lung cancer.
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Background
Interleukin-7 (IL-7) is a pleiotropic immune regulatory
protein predominantly produced by stromal cells and by
cells at the inﬂammatory sites [1]. IL-7 is a fundamental
factor for the early development of lymphocytes and a
regulator of peripheral T-cell homeostasis by modulating
the expansion of peripheral T-cell populations in states of
T-cell depletion [2]. IL-7 stimulates the progression of
some types of lymphomas, leukemias and HIV [3–5]. IL-7
produced by some human solid tumors suggests its
potential impact on the process of tumorigenesis [6, 7]. But
it is unclear how IL-7 is involved in solid tumor develop-
ment and progression. The studies on breast cancer
describe a quantitative association between the IL-7 sig-
naling complex and some clinicopathological parameters:
there is a trend toward a higher expression of IL-7 and
molecules of its signaling pathway in breast cancer patients
with poor prognosis [7]. Previously, we found that the
higher expression IL-7/IL-7 receptor (IL-7R) was corre-
lated well with clinical stages, the lymph node metastasis,
and short survival in human non-small cell lung cancer
(NSCLC) patients [8]. Moreover, IL-7/IL-7R mRNA is
detected in different tumors, such as colorectal [9], renal
[10], and central nervous system cancers [11]. Following
the binding of IL-7R to its ligand, a series of intracellular
phosphorylation events occurred, such as the activation of
the Janus kinases (JAK-1 and JAK-3), phosphoinositide 3
kinase (PI3K), and the signal transducers and activators of
transcription (STAT-5) [12]. It is tempting to speculate that
certain unidentiﬁed downstream gene(s) of IL-7 may have
a role in tumor cell proliferation. In a previous study, we
found that vascular endothelial growth factor (VEGF)-D
was one of the major downstream genes of IL-7 to regulate
lymph angiogenesis in lung cancer [8].
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DOI 10.1007/s00262-011-1078-3In this study, we tried to ﬁnd IL-7 downstream genes of
cell proliferation and study the mechanism of IL-7 induc-
ing proliferation of tumor cells in vitro and in vivo.
Methods
Antibodies and reagents
Anti-IL-7 (mouse monoclonal, sc-365306), IL-7R (rabbit
polyclonal, sc-662), cyclin C (rabbit polyclonal, sc-5610),
cyclin D1 (mouse monoclonal, sc-450), cyclin E (mouse
monoclonal, sc-25303), c-Jun (mouse monoclonal, sc-
166540), phosphorylated c-Jun (p-c-Jun) (mouse mono-
clonal, sc-882), c-Fos (mouse monoclonal, sc-8047), and
b-actin (mouse monoclonal, sc-81178) antibody were
purchased from Santa Cruz Biotechnology (USA). 3,30-
diaminobenzidine tetrahydrochloride (DAB) was pur-
chased from MaiXin Biotechnology (China). Separation
Columns and Protein G MicroBeads were purchased from
Miltenyi Biotec (Germany). Recombinant human IL-7 was
purchased from Chemicon International (USA). AP-1
inhibitor (SP600125) was purchased from Calbiochem Co.
(Germany).
Cell culture and siRNA
Human lung cancer cell lines A549 and LH7 (large cell
carcinoma) were maintained in Dulbcco’s Modifed Eagle
Medium (DMEM) supplemented with 10% fetal bovine
serum (Gibco, USA), 100 units/ml streptomycin, and
100 units/ml penicillin in a humidiﬁed 5% v/v CO2
atmosphere.
For siRNAs transfections, 10
5 cells were plated in
6-well dishes and serum starved for 24 h before cells were
infected with siRNAs (si-cyclin D1 sc-29286 and si-IL-7R
sc-35664 Santa Cruz, USA) and Lipofectamine
TM 2000
reagent (Invitrogen).
In vitro cell growth assays
In 200 ll of medium, 10
3 cells were plated in a 96-well
plate and incubated for 24, 48, and 72 h. Added to each
well was 20 ll of 5 mg/ml MTT (3-[4, 5–2-yl]- 2,5-
diphenyl tetrazolium bromide; Sigma). After a 4 h incu-
bation, the medium containing MTT was removed and
replaced with 150 ll of dimethyl sulfoxide (DMSO;
Sigma) for further incubation for 10 min until the formazan
was dissolved. The optical density (OD) value of each well
was measured using a microplate reader (Spectra Thermo,
USA) with a test wavelength of 490 nm. The wells con-
taining only the medium were used as controls. The pro-
liferation curve was plotted.
Flow cytometry (FACS, ﬂuorescence-activated
cell sorting)
A549 and LH7 cells were starved for 48 h and then stim-
ulated with serum for the indicated time periods. Wherever
indicated, 24 h post-transfected cells were subjected to
serum-starvation for another 24 h. Flow cytometry of cells
was done as described [13].
Western blot analysis
Total protein was extracted with lysis buffer (150 mM
NaCl, 1% v/v NP-40, 0.1% v/v SDS, 2 lg/ml aprotinin,
1 mM PMSF), and 60 lg of protein lysates were separated
on a 12% v/v SDS–polyacrylamide electrophoresis gel,
transferred to Polyvinylidene Fluoride (PVDF) membranes.
Proteins were visualized with horse-radish peroxidase-
conjugated goat anti-rabbit and anti-mouse IgG (Zhong-
shan, Beijing, China) followed by DAB. Subsequently,
densitometric analyses of the bands were performed.
RNA isolation and reverse transcriptase-PCR
Total RNA was isolated from cells in the logarithmic
growth phase using TRIZOL (Invitrogen, USA). The PCR
primers are listed in Table 1.
Co-immunoprecipitation (CoIP)
The protein was extracted with cellular lysis buffer. Equal
amounts of protein were incubated with c-Jun-speciﬁc
antibody immobilized onto protein G-bead for 1 h at 4C
with gentle rotation. Beads were washed extensively with
Table 1 PCR primer sequences used
Cyclin C
Fwd 50-CATGTGTGTTTCTGGCATCC-30
Rev 50-TCCGTCCTGTAGGTGTCATTC-30
Product length 295 bp
Cyclin D1
Fwd 50-CCGTCCATGCGGAAGATC-30
Rev 50-CCTGTCCTACTACCGCCTCA-30
Product length 529 bp
Cyclin E
Fwd 50-TTCTTGAGCAACACCCTCTTCTGCAGCC-30
Rev 50-TCGCCATATACCGGTCAAAGAAATCTTGTGCC-30
Product length 138 bp
b-actin
Fwd 50-AAATCGTGCGTGACATTAA-30
Rev 50-CTCGTCATACTCCTGCTTG-30
Product length 513 bp
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detected with c-Fos antibody by Western blot analysis.
Chromatin immunoprecipitation (CHIP)
We performed the ChIP assay according to the instructions
of the ChIP assay kit (Upstate, USA). The procedure
included DNA–protein cross-linking in chromatin, shearing
DNA into smaller fragments, immunoprecipitation with
anti-c-Jun antibody (negative control with normal rabbit
IgG), followed by PCR identiﬁcation of associated DNA
sequences. The PCR primer sequences designed according
to cyclin D1 promoter are the following: forward (50-CAG
TCC CAG GGC AAA TTC TA-30) and reverse (50-TTA
ACC GGG AGA AAC ACA CC-30). The PCR product is
200 bp. The positive control group used total DNA.
Experiment on nude mice with xenograft tumors
Forty male BALB/c nude (nu/nu) mice (Chinese Academy
of Medical Sciences) were used, 4 weeks of age at the start
of the experiment (17–18 g). The animals were maintained
under speciﬁc pathogen-free conditions. A549 cells
(2 9 10
6 per mouse) were injected subcutaneous in 100 ll
serum-free medium. All of the animals were randomly
divided into four groups when the maximum diameter of
the tumor reached 5–7 mm. There were ten mice in each
group. In the Group A mice, 100 ll of recombinant human
IL-7 (20 lg/ml/kg) in of serum-free medium was directly
injected into the tumor once every 2 days. The group B
mice were injected with 100 ll of IL-7R-speciﬁc antibody
(sc-662, 100 lg/ml/kg) in of serum-free medium once
every 2 days. The group C mice were administered with
SP600125 (25 lmol/ml/kg) in of serum-free medium once
every 2 days. The group D comprised control mice that
were injected with 100 ll serum-free medium once every
2 days. The tumor volume was excised once a week. The
tumor volume was calculated by the formula: vol-
ume = (width)
2 9 length/2. Data are presented as the
mean ± SD. The growth curve of the tumor was drawn.
Mice were killed by depleting 6 weeks after the ﬁrst
treatment, and tumors were excised and weighed. The
fraction of every tumor from every animal the tumor tissue
was frozen instantly for RT-PCR, western blot, CoIP, and
CHIP detecting.
Patients and specimens
A total of 100 cases of NSCLC were obtained from the
January 1, 1980 to the December 31, 2005 at the First
Afﬁliated Hospital of China Medical University, Shenyang,
China. The tumor tissues in this study were from patients
who had NSCLC proved by pathological diagnosis without
distant metastasis. None of the 100 cases had received
radiation therapy or chemotherapy before surgery. The
TNM staging system of the UICC (1997) was used to
classify the specimens. In these cases, 57 showed lymph
node metastasis (Table 2). The survival time was calcu-
lated from the operation day to death via the evaluation of
recurrence and metastasis or until the last follow-up date
(December 2006). The following-up of the surviving
patients averaged 23.09 months and ranged from 1 to
117 months. The study has been approved by the Hospi-
tals’ Ethical Review Committee.
Immunohistochemistry
Four-micron-thick sections were prepared from the par-
afﬁn-embedded formalin-ﬁxed tissues. Immunostaining
was performed by the streptavidin-peroxidase (S-P)
method (Ultrasensitive
TM MaiXin, Fuzhou, China). The
primary antibodies were anti-IL-7, anti-IL-7R, and anti-
cyclin D1 (1:100, 1:100, 1:150) antibodies. The peroxi-
dase reaction was developed with DAB. For negative
control, the primary antibodies were replaced by non-
immune serum.
We counted 200 tumor cells and calculated the per-
centage of positively stained cells. The proportion of cells
exhibiting IL-7, IL-7R, and cyclin D1 expression was
categorized as follows: 0, absent; 1, 1–25%; 2, 26–50%; 3,
51–75%; 4, more than 75%. The staining intensity was
categorized as follows: 1, weak; 2, moderate; 3, strong. The
proportion and intensity scores were then multiplied to
obtain a total score. A score \3 was considered low
expression.
Statistical analysis
The statistical package SPSS13.0 (SPSS incorporated,
Chicago) was used for all analysis. The Chi-square test,
Kaplan–Meier curves, t test, log-rank, and Cox regression
multivariate analysis were used to analyze data. Values of
P\0.05 were considered statistically signiﬁcant.
Results
IL-7/IL-7R promote the proliferation of cells
in lung cancer cell lines
Using MTT approach, we found that lung cancer A549 and
LH7 cells proliferation (P\0.05) was promoted after
incubation with the IL-7 (20 ng/ml) and inhibited with
siRNA blocking IL-7R (Fig. 1). Thus, IL-7 could promote
the proliferative ability of A549 cell by IL-7R.
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in lung cancer cell lines
TheFACSanalysisclearlyindicatedthatIL-7couldpromote
G1/S-phase transition in A549 and LH7 cells. However,
siRNA against IL-7R inhibited G1/S-phase progression in
A549 and LH7 cells (Fig. 2). It suggested that IL-7 could
facilitate cells into S-phase of cell cycle via IL-7R.
IL-7/IL-7R regulate the cell cycle by cyclin D1
in lung cancer cell lines
Cyclin C, D1, E are essential for cellular progression
through the G1 phase of the cell cycle and initiation of
DNA replication. We explored if IL-7 accelerated G1/S-
phase progression of cell cycle via three regulators. We
found that treatment of A549 and LH7 cells with recom-
binant human IL-7 increased the expression of cyclin D1
mRNA and protein (Fig. 3), while the expression of cyclin
C and E mRNA and protein were not affected in A549 and
LH7 cells after IL-7 stimulation. Then, we detected the
expression of cyclin C, D1, and E mRNA and protein of
A549 and LH7 cells after blocking IL-7R with siRNA.
Blockage of IL-7R decreased the expression of cyclin D1
mRNA and protein, which did not affected the expression
of cyclin C and E mRNA and protein (Fig. 3). It suggested
that IL-7 could up-regulate cyclin D1 via IL-7R. It sug-
gested that IL-7 could up-regulate via cyclin D1.
Table 2 Relationship between
cyclin D1 expression in NSCLC
and clinical pathological factors
(Chi-square test)
IL-7 Interleukin-7, IL-7R IL-7
receptor, NSCLC non-small cell
lung cancer
Patients Cyclin D1 high expression (%) P value R value
Gender
Male 74 33 (44.59%)
Female 26 16 (61.54%) 0.173
Age
B60 56 29 (51.79%)
[60 44 20 (45.45%) 0.552
Histology
Squamous cancer 59 27 (45.764%)
Adenocarcinoma 41 22 (53.66%) 0.399
Differentiation
Well and moderate 55 44 (63.8%)
Poor 45 30 (75%) 0.257
Stage
I–II 46 19 (41.3%)
III 54 30 (55.56%) 0.167
Lymph node metastasis
Positive 57 30 (52.63%)
Negative 43 19 (44.19%) 0.426
IL-7 expression
Positive 61 38 (62.3%)
Negative 39 11 (28.21%) 0.001 11.063
IL-7R expression
Positive 62 36 (58.06%)
Negative 38 13 (34.21%) 0.025 5.365
Fig. 1 IL-7 promoting the
growth of cell in lung cancer
cell lines. MTT analysis
showing IL-7 inducing cells
proliferation of lung cancer
A549 (a), LH7 (b) cells, and
blocking IL-7R with siRNA IL-
7R inhibiting these cells
proliferation
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sion of cyclin D1 to accelerate G1/S-phase progression in
lung cancer cell lines, we observed the change cell cycle of
A549 and LH7 with siRNA inhibiting cyclin D1. The result
of FACS showed that the change cell cycle was similar
with blocking IL-7R with siRNA (Fig. 4). It suggested that
IL-7/IL-7R could up-regulate S-phase entry via cyclin D1.
IL-7/IL-7R induce cyclin D1 via c-Fos/c-Jun pathway
To investigate how IL-7/IL-7R regulated cyclin D1, we
checked the expression of AP-1 protein in A549 and LH7
cells. Incubation of the cells with IL-7 increased the
expression of c-Fos, c-Jun, and p-c-Jun protein, while
blocking IL-7R with siRNA decreased the expressions of
c-Fos, c-Jun, and p-c-Jun (Fig. 5).
To conﬁrm whether IL-7/IL-7R up-regulated cyclin D1
through activation of c-Fos/c-Jun, then we inhibited the
activity of c-Fos/c-Jun with a speciﬁc AP-1 inhibitor
SP600125. RT-PCR and Western blotting analyses showed
that the expressions of cyclin D1 mRNA and protein in
A549 and LH7 cells were decreased signiﬁcantly after
treatment with SP600125, while decreased expression of
cyclin D1 was not affected by the IL-7 (Fig. 6). These
results imply that IL-7/IL-7R up-regulate cyclin D1 via
c-Fos/c-Jun.
IL-7/IL-7R enhance the DNA-binding activity
of AP-1 to the promoter of cyclin D1
AP-1 is a transcription factor that binds to the promotor of
speciﬁc target gene to regulate its transcription. c-Fos and
c-Jun could form heterodimer to enhance its activity [14].
We had found that IL-7/IL-7R promote the formation of
c-Fos/c-Jun heterodimer in previous study [8]. To examine
whether AP-1 binds to cyclin D1 promoter, we ﬁrst ana-
lyzed promoter sequence of cyclin D1 gene and identiﬁed
AP-1 binding sites (consensus sequence 50-TGAG/CTCA-
30), also known as TPA-responsive elements (TREs). We
then performed CHIP assay. CHIP analysis demonstrated
that AP-1 could bind to cyclin D1 promoter. Then, we
detected AP-1 DNA-binding activity in A549 cell after
incubation with the IL-7 or transfection with siRNA IL-7R.
IL-7 enhanced AP-1 binding to cyclin D1 promoter, while
blocking IL-7R reduced AP-1 binding to cyclin D1 pro-
moter (Fig. 7).
Fig. 2 IL-7 accelerates G1/S-phase progression in lung cancer cell
lines. The FACS analysis indicated that IL-7 could promote G1/S-
phase transition in A549 (a) and LH7 (b) cells. However, siRNA
against IL-7R inhibited G1/S-phase progression in A549 and LH7
cells
Fig. 3 IL-7 up-regulates cyclin
D1 in lung cancer cell lines. The
RT-PCR and Western blot
analysis showing induction
expression of cyclin D1 mRNA
and protein after Il-7 stimulation
and reduction expression of
cyclin D1 mRNA and protein
after blocking IL-7R with
siRNA IL-7R in A549 (a, b) and
LH7 (c, d) cells. However, after
Il-7 stimulation or blocking IL-
7R with siRNA, IL-7R did not
affect the expression of cyclin C
and cyclin E protein and mRNA
in A549 (a, b) and LH7 (c,
d) cells
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To examine whether IL-7 regulated expression of cyclin
D1 could be observed in vivo, we next study experiment on
nudemice withxenograft tumors,respectively,withtheIL-7,
sc-662, and SP600125 treatment. We excised tumor volume
once a week and found IL-7 promotes tumors growth, and
blocking IL-7R or AP-1 inhibited tumors growth (Fig. 8),
suggesting that IL-7 could induce tumor cells growth in
vivo. Then, we found that IL-7 increased the expression of
cyclin D1 protein and mRNA levels in xenograft tumors,
and blocking IL-7R or AP-1 decreased their expression
levels (Fig. 9a, b), indicating that IL-7 could up-regulate
cyclin D1 via IL-7R in vivo. IL-7 increased the expression
of c-Fos and c-Jun, and p-c-Jun protein, while blocking IL-
7R or AP-1 decreased the expressions of c-Fos, c-Jun, and
p-c-Jun (Fig. 9c), implying that IL-7/IL-7R up-regulate
cyclin D1 via c-Fos/c-Jun in vivo. Using CoIP approach,
we found that c-Fos/c-Jun heterodimer was increased
after incubation with the IL-7, and blocking IL-7R or AP-1
decreased the dimer formation (Fig. 9d), suggesting that
IL-7/IL-7R could promote c-Fos and c-Jun to form
heterodimer. CHIP analysis demonstrated that AP-1
could bind to cyclin D1 promoter. Then, we detected
AP-1 DNA-binding activity in xenograft tumors. IL-7
e n h a n c e dA P - 1b i n d i n gt oc y c l i nD 1p r o m o t e r ,w h i l e
blocking IL-7R reduced AP-1 binding to cyclin D1
promoter (Fig. 9e) in vivo. These data implied that
IL-7/IL-7R up-regulate cyclin D1 via c-Fos/c-Jun to
tumors growth.
Expression of cyclin D1 correlate with IL-7/IL-7R level
and NSCLC patient survival
Immunohistochemical analysis of 100 NSCLC specimens
revealed that the expression of cyclin D1 was signiﬁcantly
associated with the expression of IL-7 and IL-7R (Table 2;
Fig. 10).
Clinically, the expression levels of cyclin D1 in NSCLC
did not correlated with sex, age, differentiation, clinical
stages, and lymph node metastasis. Patients with low
expression of cyclin D1 had a statistically signiﬁcantly
longer survival than those with high expression of
cyclin D1 (median survival = 10 ± 4.1 months; 95% CI
1.9–18.1 months; P = 0.000; Fig. 11). Previously, we had
found patients with low expression of IL-7 and IL-7R
survived longer. Univariate analysis showed that lymph
node metastasis, tumor stage, IL-7, IL-7R, and cyclin D1
could affect the survival. In the Cox regression multivariate
analysis, lymph node metastasis, tumor stage, and cyclin
D1 were the strongest predictors of survival (Table 3).
These results provide a possible explanation that IL-7, IL-
7R, and cyclin D1 high expression patients were more
likely to have poor prognosis, possibly resulting from IL-7/
IL-7R-mediated cell proliferation via up-regulation of
cyclin D1 in human NSCLC.
Discussion
Previous evidences had suggested the important role of
IL-7 in the pathogenesis and progression of lymphomas
Fig. 4 Down-regulating cyclin D1 inhibit G1/S-phase progression in
lung cancer cell lines. The FACS analysis indicated that siRNA
against cyclin D1 inhibited G1/S-phase progression in A549 (a) and
LH7 (b) cells
Fig. 5 IL-7 up-regulates the expression and phosphorylation of
c-Fos, c-Jun in lung cancer cell lines. Western blot analysis showing
up-regulation of c-Fos, c-Jun, and p-c-Jun proteins in A549 (a) and
LH7 (b) cells treated with IL-7, and blocking IL-7R with siRNA
IL-7R down-regulating the expression of c-Fos, c-Jun, and p-c-Jun
proteins
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growth of cells, while this effect involved PI3K and Jak3
[16].
In the present study, we found IL-7 promoted cell
growth. Then, we detected the effect of IL-7 to cell cycle.
The result suggested that IL-7 could regulate G1/S stage of
cell cycle. Cyclin C, D1, and E were important members of
the G1 cyclin family involved in the regulation of the G1/S
transition of the cell cycle [17]. We examined whether IL-7
was interrelated with cyclin C, D1, or E in lung cancer cell.
We obtained that recombinant human IL-7 increased the
expression of cyclin D1 mRNA and protein in lung cancer
cell lines, and blocking IL-7R with siRNA could abolish
the role of IL-7 on cyclin D1. But the recombinant human
IL-7 and blocking IL-7R with siRNA did not affect cyclin
C and E. The cyclin D1 was frequently overexpressed in a
wide range of cancers. The nuclear accumulation of cyclin
D1 induced uncontrolled proliferation in normal human
cells, which could facilitate the development of invasive
cancer [18]. In addition, the result of FACS showed that the
change cell cycle was similar with blocking IL-7R with
siRNA. It suggested that IL-7/IL-7R could up-regulate
S-phase entry via cyclin D1.
The cyclin D1 expression was under complex regulation
and markedly inﬂuenced by the activator protein-1 (AP-1),
NF-kB, and b-catenin/T-cell factor (TCF) signaling path-
ways [19–21]. A number of compounds targeting these
signaling pathways could indirectly attenuate the cyclin D1
expression to mediate cell cycle arrest.
Previously, we found IL-7 induced c-Fos, c-Jun
expression, and phosphorylation, promoted c-Fos and c-Jun
heterodimer formation, and enhanced the activity of c-Fos/
c-Jun. AP-1 was a sequence-speciﬁc transcription factor
composed of homodimers of the Jun family (c-Jun, Jun D,
and Jun B) or heterodimers of the Jun family members with
any of the Fos family members (c-Fos, Fos B, Fra1, and
Fra2). AP-1 had long been associated with proliferation.
AP-1 directed the expression of a critical target gene or
genes, in response to cytokines, stress, and mitogenic sig-
nals. A common feature of all these proteins was the
evolutionarily conserved bZIP domain, the collective term
for a basic DNA-binding domain combined with a leucine
zipper region. The leucine zipper was responsible for
dimerization, which was a prerequisite for DNA binding
mediated by the basic domain. AP-1 had long been asso-
ciated with proliferation [22]. We found that AP-1 can bind
to cyclin D1 promoter. Consistent with our ﬁnding, it had
been shown that berberine inhibited cyclin D1 expression
via suppressing binding of AP-1 transcription factors to
CCND1 AP-1 motif [23].
In nude mice xenograft tumors, we obtained IL-7 could
induce tumor growth, up-regulate the expressions of c-Fos,
c-Jun, p-c-Jun, and cyclin D1, and promote AP-1 binding
activity. This result was consistent with it in lung cancer
cell lines.
Immunohistochemicalanalysisof100NSCLCspecimens
revealed the positive expression of IL-7, IL-7R, and cyclin
D1 in lung cancer cells. It had been shown that a few colon
cancer cells could produce IL-7, breast cancer tissues
expressed IL-7 and IL-7R, and IL-7R positively correlated
Fig. 6 Inhibiting AP-1 down-regulating the level of cyclin D1
expression in lung cancer cell lines. The RT-PCR and Western blot
analysis showing reduction in cyclin D1 mRNA and protein after
inhibiting AP-1 with AP-1-speciﬁc inhibitor SP600125 in A549
(a) and LH7 (b) cells
Fig. 7 IL-7 enhances the DNA-binding activity of AP-1 to the
Promoter of Cyclin D1. The CHIP analysis showing that AP-1 (c-Fos/
c-Jun) could bind with cyclin D1 promoter, and the activity of binding
was enhanced by IL-7 in A549 cell line. However, inhibiting IL-7R
with siRNA IL-7R decreased the activity of binding AP-1 with cyclin
D1 promoter
Fig. 8 IL-7 promoting the growth of xenograft tumors of nude mice.
The growth curve of the tumor analysis showing IL-7 inducing
xenograft tumors proliferation, and blocking IL-7R or inhibiting AP-1
inhibiting xenograft tumors proliferation in nude mice
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In previous study, we found that the high expression of IL-7
and IL-7R correlated well with lymph node metastasis and
poor prognosis [8]. In this study, we further evaluated
expression of cyclin D1 in 100 of NSCLC tissues. The
expression of cyclin D1 was positive in lung cancer cells.
Interestingly,wehadfoundthatthehighexpressionofcyclin
D1 correlated well with high expression of IL-7 and IL-7R
and shorter survival rate of patients. Cox regression multi-
variateanalysisshowedlymphnodemetastasis,tumorstage,
and cyclin D1 were the strongest predictors of survival.
Conclusion
In this study demonstrated that, in vivo and in vitro, IL-7
and its receptor IL-7R, were able to induce cyclin D1 gene
expression via AP1 (c-Fos/c-Jun)-dependent pathway to
promote cell growth in human lung cancer. In situ analysis
of human, NSCLC revealed that overexpression of IL-7/IL-
7R and cyclin D1 played an important role in lung cancer
development. We inhibited IL-7R to reduce cell prolifer-
ation in lung cancer. Thus, targeting IL-7/IL-7R may
potentiate new therapeutic strategy against tumors.
Fig. 9 The RT-PCR and
Western blot analysis showing
induction of cyclin D1 mRNA
and protein after Il-7 stimulation
and reduction in cyclin D1
mRNA and protein after
blocking IL-7R or inhibiting
AP-1 in nude mice (a, b).
Western blot analysis showing
up-regulation of c-Fos, c-Jun,
and p-c-Jun proteins in nude
mice treated with IL-7, and
blocking IL-7R with IL-7R-
speciﬁc antibody (sc-662) or
inactivating AP-1 with AP-1
inhibitor (SP600125) down-
regulating the expression of
c-Fos, c-Jun, and p-c-Jun
proteins (c). IL-7 could induce
the formation of AP-1 (c-Fos/
c-Jun) heterodimmer via IL-7R
with CoIP method in vivo (d).
The CHIP analysis showing that
AP-1 (c-Fos/c-Jun) could bind
with cyclin D1 promoter, and
the activity of binding were
enhanced by IL-7 in xenograft
tumors (e)
Fig. 10 The expressions of cyclin D1 in NSCLC correlates with the
level of IL-7 and IL-7R. Immunohistochemical straining of consec-
utive serial sections of NSCLC tissues. Brown-yellow particles of
IL-7 (a), IL-7R (b), and cyclin D1 (c) were observed in cancer cells
(relationship between cyclin D1 expression with IL-7 (P = 0.001,
R = 11.063) and with IL-7R (P = 0.025, R = 5.365); 400 9
magniﬁcation)
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